This suggests that CD36 can be used as a specific target for fatty acid metabolism of macrophages in lung cancer and breast cancer to improve the tumor microenvironment while reducing the influence of M2-type macrophages in other normal tissues, thus reducing the damage to the autoimmune system. Here, CD36 is linked to lung carcinoma.